Estrella Immunopharma Inc (ESLA)

$0.99 +0.02 (2.06%)
Market Cap 39.28M
Revenue (ttm) 0.00
Net Income (ttm) -7.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 124,800
Avg Vol 191,514
Day's Range N/A - N/A
Shares Out 37.77M
Stochastic %K 7%
Beta 0.55
Analysts Strong Sell
Price Target $16.00

Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 318 9098
Address:
5858 Horton Street, Suite 370, EmeryVille, United States
BonjerminFranklin
BonjerminFranklin Jan. 12 at 10:08 PM
$ESLA tomorrow we hit .90 cents!!
1 · Reply
BonjerminFranklin
BonjerminFranklin Jan. 9 at 5:02 PM
$ESLA below $1 soon! Then LOAD the boat for a double up!
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 7 at 8:44 PM
BioMedNewsBreaks – $ESLA, $ESLAW Closes $8.0 Million Registered Direct Offering https://ibn.fm/ALEls
0 · Reply
JohnTrack
JohnTrack Jan. 7 at 12:42 AM
$ESLA letting price do the talking...
0 · Reply
stinstewart
stinstewart Jan. 6 at 10:03 PM
$ESLA same scenario as last raise, even tho at above market price, the stock tanked, but then strongly rebounded and went to 3$. Hopefully, once investors see that in this case, this time around, it was one specific huge investor who must believe, the stock will come to its senses and start the climb again.
0 · Reply
JohnTrack
JohnTrack Jan. 6 at 8:28 PM
$ESLA offering closed and now what https://www.rapidticker.com/news/esla-estrella-immunopharma-announces-closing-of-6c1ca6
0 · Reply
BonjerminFranklin
BonjerminFranklin Jan. 6 at 2:16 PM
$ESLA Going under $1 by the looks of it.
0 · Reply
JohnTrack
JohnTrack Jan. 5 at 9:33 PM
$ESLA $8.0 Million Registered Direct Offering https://www.rapidticker.com/news/esla-estrella-immunopharma-inc-announces-80-10ab61
1 · Reply
topstockalerts
topstockalerts Jan. 5 at 6:49 PM
Estrella Immunopharma announced definitive agreements for a registered direct offering and a concurrent private placement totaling $8 million. The market-priced transaction consists of 5,063,290 units at $1.58 per unit, with each unit including one common share or a pre-funded warrant and 1.5 investor warrants exercisable at $1.39 per share. The offering involves a single healthcare-focused institutional investor and is expected to close around January 6, 2026, subject to customary conditions. Aegis Capital Corp is serving as the exclusive placement agent. Proceeds will be used for general corporate purposes and working capital. The company said the stock decline reflects typical market reaction to potentially dilutive equity offerings. Pre-funded warrants are immediately exercisable at a nominal price, while investor warrants carry a $1.39 exercise price. $ESLA
0 · Reply
DARKP00L
DARKP00L Jan. 5 at 1:46 PM
$ESLA 08:32 on Jan. 05 2026 Estrella Immunopharma Announces Registered Direct Offering And Concurrent Private Placement; Aggregate Gross Proceeds From Both Transactions Expected To Be ~$8M #tradeideas
0 · Reply
Latest News on ESLA
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Jan 6, 2026, 2:02 PM EST - 10 days ago

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Jan 5, 2026, 8:30 AM EST - 11 days ago

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Dec 4, 2025, 8:00 AM EST - 6 weeks ago

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Nov 3, 2025, 8:00 AM EST - 2 months ago

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Oct 6, 2025, 8:00 AM EDT - 3 months ago

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jun 5, 2025, 8:00 AM EDT - 8 months ago

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Jun 3, 2025, 8:00 AM EDT - 8 months ago

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

May 29, 2025, 8:01 AM EDT - 8 months ago

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Mar 5, 2025, 8:00 AM EST - 11 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 21, 2025, 8:30 AM EST - 11 months ago

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Feb 19, 2025, 4:46 PM EST - 11 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Sep 27, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Aug 14, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Sep 29, 2023, 10:34 AM EDT - 2 years ago

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Estrella Immunopharma Nears Completion Of SPAC Listing

Sep 19, 2023, 1:30 AM EDT - 2 years ago

Estrella Immunopharma Nears Completion Of SPAC Listing

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Sep 18, 2023, 5:00 PM EDT - 2 years ago

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Oct 3, 2022, 7:27 AM EDT - 3 years ago

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

BonjerminFranklin
BonjerminFranklin Jan. 12 at 10:08 PM
$ESLA tomorrow we hit .90 cents!!
1 · Reply
BonjerminFranklin
BonjerminFranklin Jan. 9 at 5:02 PM
$ESLA below $1 soon! Then LOAD the boat for a double up!
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 7 at 8:44 PM
BioMedNewsBreaks – $ESLA, $ESLAW Closes $8.0 Million Registered Direct Offering https://ibn.fm/ALEls
0 · Reply
JohnTrack
JohnTrack Jan. 7 at 12:42 AM
$ESLA letting price do the talking...
0 · Reply
stinstewart
stinstewart Jan. 6 at 10:03 PM
$ESLA same scenario as last raise, even tho at above market price, the stock tanked, but then strongly rebounded and went to 3$. Hopefully, once investors see that in this case, this time around, it was one specific huge investor who must believe, the stock will come to its senses and start the climb again.
0 · Reply
JohnTrack
JohnTrack Jan. 6 at 8:28 PM
$ESLA offering closed and now what https://www.rapidticker.com/news/esla-estrella-immunopharma-announces-closing-of-6c1ca6
0 · Reply
BonjerminFranklin
BonjerminFranklin Jan. 6 at 2:16 PM
$ESLA Going under $1 by the looks of it.
0 · Reply
JohnTrack
JohnTrack Jan. 5 at 9:33 PM
$ESLA $8.0 Million Registered Direct Offering https://www.rapidticker.com/news/esla-estrella-immunopharma-inc-announces-80-10ab61
1 · Reply
topstockalerts
topstockalerts Jan. 5 at 6:49 PM
Estrella Immunopharma announced definitive agreements for a registered direct offering and a concurrent private placement totaling $8 million. The market-priced transaction consists of 5,063,290 units at $1.58 per unit, with each unit including one common share or a pre-funded warrant and 1.5 investor warrants exercisable at $1.39 per share. The offering involves a single healthcare-focused institutional investor and is expected to close around January 6, 2026, subject to customary conditions. Aegis Capital Corp is serving as the exclusive placement agent. Proceeds will be used for general corporate purposes and working capital. The company said the stock decline reflects typical market reaction to potentially dilutive equity offerings. Pre-funded warrants are immediately exercisable at a nominal price, while investor warrants carry a $1.39 exercise price. $ESLA
0 · Reply
DARKP00L
DARKP00L Jan. 5 at 1:46 PM
$ESLA 08:32 on Jan. 05 2026 Estrella Immunopharma Announces Registered Direct Offering And Concurrent Private Placement; Aggregate Gross Proceeds From Both Transactions Expected To Be ~$8M #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 5 at 1:43 PM
$ESLA 08:32 on Jan. 05 2026 Estrella Immunopharma Announces Registered Direct Offering And Concurrent Private Placement; Aggregate Gross Proceeds From Both Transactions Expected To Be ~$8M #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 5 at 1:38 PM
$ESLA 08:32 on Jan. 05 2026 Estrella Immunopharma Announces Registered Direct Offering And Concurrent Private Placement; Aggregate Gross Proceeds From Both Transactions Expected To Be ~$8M #tradeideas
0 · Reply
NylonNod
NylonNod Dec. 27 at 12:47 PM
$ESLA Confidence will depend on whether guidance becomes dependable; organic growth must prove sustainable without incentives — consistent delivery could invite longer‑term shareholders. Until validation appears, volatility remains the default.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 27 at 3:40 AM
$ESLA
0 · Reply
BackwardationV2
BackwardationV2 Dec. 25 at 1:16 PM
$ESLA The strategic path forward will be judged on practical milestones, not narrative strength. The market is increasingly intolerant of delays that stretch credibility. If milestones arrive on time, perception can shift faster than fundamentals. Investors will likely wait for pattern recognition before re‑committing capital.
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 4:52 PM
$ESLA update just released... https://www.rapidticker.com/news/esla-sec-filing-072f23
0 · Reply
Colonia
Colonia Dec. 19 at 3:25 PM
$ESLA I see a large buy order pending. Extension on phase II? $TSLA holding for 100% $BTC watching for a potential increase in position $IRBT people still buying this? $SAVA ouch!
0 · Reply
topstockalerts
topstockalerts Dec. 4 at 2:58 PM
Estrella Immunopharma said its CD19-targeted cancer therapy received clearance to advance into Phase II testing. An independent safety board recommended moving its STARLIGHT-1 trial into an expansion phase after a favorable safety review of EB103 for relapsed or refractory B-cell non-Hodgkin lymphoma. The Phase I dose-escalation stage showed no treatment-related serious adverse events in nine patients, many considered high risk, and the high-dose cohort achieved a 100% complete response rate at Month 1. Estrella called this a major milestone, noting EB103’s strong safety profile and full responses suggest it may overcome toxicity challenges that have historically limited CD19-targeted CAR-T therapies. The expansion phase will further evaluate safety and early efficacy at the recommended Phase II dose. $ESLA
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 1:15 PM
$ESLA there it goes … 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
www_larval_com
www_larval_com Nov. 17 at 8:53 PM
$CYPH -7%[-12%] $MIST 6%[17%] $ESLA -4%[-17%] $ONEG 4%[-58%] $VENU -4%[-20%] most notable movement into the final minutes of trading.
0 · Reply
www_larval_com
www_larval_com Nov. 12 at 8:52 PM
$CYPH 7%[387%] $ESLA 4%[-16%] $CMCT 4%[93%] $FTCI 3%[47%] $WLDS 3%[39%] most notable movement into the final minutes of trading.
0 · Reply
WendyMorell1077
WendyMorell1077 Nov. 6 at 4:04 PM
$ESLA attracts attention as electric and automation themes rise. AITX demonstrates sector leadership through next-generation perimeter monitoring technologies.
0 · Reply